viernes, 22 de diciembre de 2017

Gene Therapy Approved for Rare Inherited Vision-Loss Disorders: MedlinePlus Health News

Gene Therapy Approved for Rare Inherited Vision-Loss Disorders: MedlinePlus Health News

MedlinePlus Trusted Health Information for You

Gene Therapy Approved for Rare Inherited Vision-Loss Disorders

By Scott Roberts
Tuesday, December 19, 2017
TUESDAY, Dec. 19, 2017 (HealthDay News) -- Luxturna, a form of gene therapy, has been approved to treat a rare group of inherited vision disorders that can lead to blindness.
The disorders are broadly grouped together and known as biallelic RPE65 mutation-associated retinal dystrophy. They affect a combined 1,000 to 2,000 people in the United States, the U.S. Food and Drug Administration said Tuesday in a news release.
Luxturna (voretigene neparvovec-rzyl) delivers a working copy of an existing defective gene that produces a retinal enzyme needed for normal vision.
"Today's approval marks another first in the field of gene therapy, both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss," said FDA Commissioner Dr. Scott Gottlieb. "I believe gene therapy will become a mainstay for treating, and maybe curing, many of our most devastating and intractable illnesses."
Luxturna should be given only to people who have treatment-capable retinal cells, the agency said. Treatment must be done separately on each eye, at least six days apart.
The treatment was evaluated in clinical trials involving 41 people ranging in age from 4 to 44. The most common side effects included eye redness, cataracts, increased eye pressure and retinal tear.
Luxturna is produced by Spark Therapeutics, based in Philadelphia.
SOURCE: Dec. 19, 2017 press release, U.S. Food and Drug Administration
News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.
More Health News on
Genes and Gene Therapy
Vision Impairment and Blindness

No hay comentarios:

Publicar un comentario